Market Research Logo

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Summary

Amyotrophic Lateral Sclerosis (ALS) is often referred to as Lou Gehrig's Disease after the famous baseball player who was diagnosed with the disease in 1939. Amyotrophic Lateral Sclerosis (ALS) is a rare but fatal progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. Amyotrophic Lateral Sclerosis (ALS) severely impacts physical functioning, and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with Amyotrophic Lateral Sclerosis (ALS) lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death.

In 2017, the 7MM had 46,240 diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS). This is expected to increase to 52,712 diagnosed prevalent cases by 2027, at an Annual Growth Rate (AGR) of 1.40%. The increase is driven by the aging population in the 7MM. In 2017, the 7MM had 53,024 total prevalent cases of Amyotrophic Lateral Sclerosis (ALS). This is expected to increase to 60,304 total prevalent cases by 2027, at an AGR of 1.37%. The US had the highest number of diagnosed prevalent and total prevalent cases of Amyotrophic Lateral Sclerosis (ALS).

Epidemiologist forecasts that all markets will see an increase in the diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS)during the forecast period. However, the development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

The report Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027, provides an overview of the risk factors, comorbidities, and the global and historical trends for Amyotrophic Lateral Sclerosis (ALS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS).

Scope

  • The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report provides an overview of the risk factors and global trends of ALS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 40 years and older across the 7MM: 10-year epidemiological forecast for the total (medically diagnosed and undiagnosed) and diagnosed prevalent cases of ALS. The diagnosed prevalent cases are further segmented by age (40 years and older), sex, and type of ALS based on sporadic and familial component.
  • The ALS epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The ALS Epidemiology Forecast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global ALS market.
  • Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ALS therapeutics in each of the markets covered.
  • Understand proportion of ALS population based on sporadic and familial component.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Amyotrophic Lateral Sclerosis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for ALS (2017-2027)
3.5.1 Diagnosed Prevalent Cases of ALS
3.5.2 Age-Specific Diagnosed Prevalent Cases of ALS
3.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS
3.5.4 Diagnosed Prevalent Cases of ALS by Type
3.5.5 Total Prevalent Cases of ALS
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Primary Research - Prescriber Survey
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for ALS
Table 2: High-Prescribing Physicians (Non-Key Opinion Leaders) Surveyed, By Country
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2017 and 2027
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of ALS, Ages ≥40 Years, 2017
Figure 3:Sources Used for Diagnosed Prevalent Cases of ALS
Figure 4:Sources Used for Diagnosed Prevalent Cases of ALS Type
Figure 5: 7MM, Diagnosed Prevalent Cases of ALS, Men and Women, Ages ≥40 Years, 2017
Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of ALS, Men and Women, 2017
Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of ALS, Men and Women, Ages ≥40 Years, 2017
Figure 8: 7MM, Diagnosed Prevalent Cases of ALS by Type, Men and Women, Ages ≥40 Years, 2017
Figure 9: 7MM, Total Prevalent Cases of ALS, Men and Women, Ages ≥40 Years, 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report